Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: LEVEMIR

« Back to Dashboard

Summary for Tradename: LEVEMIR

Patents:11
Applicants:1
NDAs:1
Suppliers: see list3
2013 Sales:$1,547,629,000

Pharmacology for Tradename: LEVEMIR

Ingredient-typeInsulin
Drug ClassInsulin Analog

Clinical Trials for: LEVEMIR

The Effects of Insulin Detemir and Gliclazide-MR Treatments on Endothelial Functions in Patients With Type 2 Diabetes
Status: Completed Condition: Type 2 Diabetes Mellitus

Safety Follow-up on Children and Adolescents With Type 1 Diabetes Treated With Insulin Detemir. An Extension to Trial NN304-1689
Status: Completed Condition: Diabetes; Diabetes Mellitus, Type 1

Use of Levemir® Improves Metabolic and Clinical Status in Cystic Fibrosis-related Diabetes (CFRD)
Status: Recruiting Condition: Cystic Fibrosis Related Diabetes

Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes
Status: Completed Condition: Diabetes; Diabetes Mellitus, Type 1

Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes
Status: Completed Condition: Diabetes; Diabetes Mellitus, Type 1

Comparison of Insulin Detemir and Insulin Aspart in 2 Separate Injections Twice Daily to Extemporaneous Mixing Injection Regimen Twice Daily - The Paediatric Mixing Trial
Status: Completed Condition: Diabetes; Diabetes Mellitus, Type 1

Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days
Status: Completed Condition: Alzheimer's Disease; Mild Cognitive Impairment

Evaluation of Levemir® for the Treatment of Type 1 and 2 Diabetes
Status: Completed Condition: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Safety of NovoMix® 30 or Levemir® for Treatment of Type 2 Diabetics in Macedonia
Status: Completed Condition: Diabetes; Diabetes Mellitus, Type 2

Observational Study of Safety and Tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the Treatment of Type 1 and Type 2 Diabetes Mellitus
Status: Completed Condition: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novo Nordisk Inc
LEVEMIR INNOLET
insulin detemir recombinant
INJECTABLE;SUBCUTANEOUS021536Jun 16, 2005DISCNNo5,750,497<disabled>YY<disabled>
Novo Nordisk Inc
LEVEMIR FLEXTOUCH
insulin detemir recombinant
INJECTABLE;SUBCUTANEOUS021536Oct 31, 2013RXYes5,866,538<disabled>Y<disabled>
Novo Nordisk Inc
LEVEMIR PENFILL
insulin detemir recombinant
INJECTABLE;SUBCUTANEOUS021536Jun 16, 2005DISCNNo6,869,930<disabled>YY<disabled>
Novo Nordisk Inc
LEVEMIR
insulin detemir recombinant
INJECTABLE;SUBCUTANEOUS021536Jun 16, 2005RXYes5,750,497<disabled>YY<disabled>
Novo Nordisk Inc
LEVEMIR FLEXPEN
insulin detemir recombinant
INJECTABLE;SUBCUTANEOUS021536Jun 16, 2005RXYesRE43834<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc